On Friday, Piper Sandler confirmed its Obese ranking on Tenaya Therapeutics Inc (NASDAQ:TNYA) with a gentle worth goal of $40.00. The agency’s endorsement follows Tenaya’s current announcement that the Information Security Monitoring Board (DSMB) has authorised the continuation of dosing within the second cohort of their scientific examine at a dose of 6E13 vg/kg.
The analyst from Piper Sandler famous that this growth reduces the chance related to the top-line knowledge anticipated in December. Tenaya has made a number of protocol changes that would broaden the remedy’s applicability to each non-obstructive hypertrophic cardiomyopathy (nHCM) and obstructive hypertrophic cardiomyopathy (oHCM) sufferers who don’t have implantable cardioverter defibrillators (ICDs).
These adjustments are additionally aimed toward enhancing the security profile of TN-201, Tenaya’s therapeutic candidate, and rising the pool of eligible sufferers.
The protocol alterations embody modifications to cardiac biopsies, that are supposed to offer better flexibility throughout totally different dosing regimens. This strategy is designed to enhance the understanding of the kinetics of expression and subsequently increase the chance of success (PoS) for the remedy.
The Piper Sandler analyst additionally highlighted the potential market alternative offered by pediatric MYBPC3 HCM sufferers, estimating there are roughly 3,000 such sufferers in the US alone. This demographic may characterize an extra worth proposition for Tenaya Therapeutics.
In abstract, Piper Sandler’s evaluation means that the current developments and upcoming top-line knowledge in December current a good shopping for alternative for traders. The agency stays bullish on the prospects of Tenaya Therapeutics’ shares forward of the anticipated knowledge launch.
In different current information, Tenaya Therapeutics has seen important developments in its MyPEAK-1 Part 1b/2 scientific trial for TN-201, a gene remedy for MYBPC3-associated hypertrophic cardiomyopathy. The Information Security Monitoring Board has authorised the development to Cohort 2, which entails the next dose of the remedy, and expanded the eligibility standards for members.
Moreover, Tenaya has made a number of protocol changes, together with the addition of a baseline biopsy and the potential enhance within the variety of members from 9 to 24 adults.
Tenaya anticipates the discharge of preliminary outcomes from Cohort 1 by the tip of 2024, which is able to present essential security knowledge and insights from cardiac biopsies. Analyst corporations H.C. Wainwright, Canaccord Genuity, and Leerink Companions have maintained constructive outlooks on Tenaya, with worth targets of $18, $16, and $8, respectively.
Tenaya has additionally launched a brand new 2024 Inducement Fairness Incentive Plan, permitting for the issuance of 1,200,000 shares of frequent inventory. Moreover, the corporate introduced the upcoming departure of Leone Patterson, its Chief Monetary and Enterprise Officer, and is now within the technique of trying to find a brand new CFO.
InvestingPro Insights
Latest knowledge from InvestingPro sheds extra gentle on Tenaya Therapeutics’ monetary place and market efficiency. The corporate’s market capitalization stands at $169.61 million, reflecting its present valuation within the biotech sector. Notably, Tenaya’s inventory has proven important volatility, with a 21.47% return over the previous week, however a considerable decline of 49.88% during the last six months.
InvestingPro Suggestions spotlight that Tenaya holds extra cash than debt on its steadiness sheet, which may present monetary flexibility because it advances its scientific applications. That is notably related given the corporate’s ongoing scientific examine and protocol changes talked about within the article. Nevertheless, it is essential to notice that Tenaya is shortly burning by way of money, a typical attribute of biotech corporations within the growth stage.
Traders needs to be conscious that analysts don’t anticipate the corporate to be worthwhile this 12 months, aligning with the pre-revenue stage of many clinical-stage biotech corporations. For these looking for extra complete evaluation, InvestingPro affords 8 extra ideas for Tenaya Therapeutics, offering deeper insights into the corporate’s monetary well being and market place.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.
